{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:28:28Z","timestamp":1792092508749,"version":"4.4.0"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Chief Scientist, Ministry of Agriculture, Israel","award":["Grant No. 13-18-0002."],"award-info":[{"award-number":["Grant No. 13-18-0002."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination against brucellosis using live attenuated strains is the primary approach in protecting livestock against the disease through a strong cellular immune response. Attenuated vaccine strains also induce serum anti-Brucella antibodies, mostly against Brucella O-polysaccharide, but their role in protection against the disease remains unclear. In this study, we show that Brucella OPS serum antibodies after vaccination or natural infection could kill Brucella in vitro as shown by the serum bactericidal activity (SBA) assay. We used serum samples of Rev. 1 vaccinated sheep that were negative or positive for Brucella OPS antibodies by either one of complement fixation test (CFT), microplate agglutination test (MAT) and ELISA, or sera of naturally infected sheep positive by CFT. We found a significant increase in the killing ability of sera 30 days after intraocular vaccination with Rev. 1 as compared with pre-vaccination. SBA was significantly higher in sera containing Brucella OPS IgG antibodies in comparison with sera lacking such antibodies (p &lt; 0.001 against 16M &amp; Rev. 1 strains). All 10 sera of convalescent sheep demonstrated significant killing ability against the 16M B. melitensis field strain. Specific OPS antibodies participate in the in vitro complement mediated Brucella killing suggesting a potential role in protection against the disease through this mechanism and relevance of developing OPS-based Brucella vaccines.<\/jats:p>","DOI":"10.3390\/vaccines10020317","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:26:41Z","timestamp":1645129601000},"page":"317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Natural Brucella melitensis Infection and Rev. 1 Vaccination Induce Specific Brucella O-Polysaccharide Antibodies Involved in Complement Mediated Brucella Cell Killing"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-0877","authenticated-orcid":false,"given":"Shubham","family":"Mathur","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Kimron Veterinary Institute, Beit Dagan 5025001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Banai","sequence":"additional","affiliation":[{"name":"Kimron Veterinary Institute, Beit Dagan 5025001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1874318801004010109","article-title":"Pathogenesis of Brucella spp.","volume":"4","author":"Xavier","year":"2010","journal-title":"Open Vet. Sci. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.vetmic.2009.06.021","article-title":"Brucellosis: A re-emerging zoonosis","volume":"140","author":"Seleem","year":"2010","journal-title":"Vet. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(07)70286-4","article-title":"Human brucellosis","volume":"7","author":"Franco","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","first-page":"18.1.1","article-title":"Progress in vaccine development","volume":"36","author":"Moyle","year":"2015","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/1389201014666131226123016","article-title":"Research progress in live attenuated Brucella vaccine development","volume":"14","author":"Wang","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1128\/jb.66.5.585-599.1953","article-title":"Immunization against brucella infection. I. Isolation and characterization of a streptomycin-dependent mutant","volume":"66","author":"Herzberg","year":"1953","journal-title":"J. Bacteriol."},{"key":"ref_7","unstructured":"World Health Organization (1998). The Development of New\/Improved Brucellosis Vaccines: Report of WHO Meeting, Geneva, Switzerland, 11\u201312 December 1997, World Health Organization."},{"key":"ref_8","first-page":"10","article-title":"Reemergence of Human Brucellosis in Israel","volume":"21","author":"Eljay","year":"2019","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0378-1135(02)00231-6","article-title":"Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: Laboratory aspects and field observations","volume":"90","author":"Banai","year":"2002","journal-title":"Vet. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CMR.16.1.65-78.2003","article-title":"Molecular host-pathogen interaction in brucellosis: Current understanding and future approaches to vaccine development for mice and humans","volume":"16","author":"Ko","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/iai.56.12.3251-3261.1988","article-title":"Killing of brucella abortus by bovine serum","volume":"56","author":"Corbeil","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_12","first-page":"21","article-title":"Natural resistance and innate immunity in brucellosis","volume":"1","author":"Costa","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.20506\/rst.32.1.2190","article-title":"Immunity to brucellosis","volume":"32","author":"Skendros","year":"2013","journal-title":"OIE Rev. Sci. Tech."},{"key":"ref_14","first-page":"239","article-title":"Enhancement activity of anti-brucella sera in experimental Brucella abortus infection in mice","volume":"36","author":"Forget","year":"1977","journal-title":"Rev. Can. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0769-2625(87)80052-1","article-title":"Immunity conferred upon mice by anti-LPS monoclonal antibodies in murine Brucellosis","volume":"138","author":"Limet","year":"1987","journal-title":"Ann. l\u2019Institut Pasteur Immunol."},{"key":"ref_16","first-page":"2158","article-title":"Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen","volume":"50","author":"Phillips","year":"1989","journal-title":"Am. J. Vet. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1016\/j.vaccine.2012.04.009","article-title":"Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice","volume":"30","author":"Adone","year":"2012","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1021\/acs.accounts.7b00445","article-title":"Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans","volume":"50","author":"Bundle","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.micpath.2016.05.013","article-title":"Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method","volume":"97","author":"Jang","year":"2016","journal-title":"Microb. Pathog."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Barquero-Calvo, E., Chaves-Olarte, E., Weiss, D.S., Guzm\u00e1n-Verri, C., Chac\u00f3n-D\u00edaz, C., Rucavado, A., Moriy\u00f3n, I., and Moreno, E. (2007). Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000631"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/acscentsci.7b00019","article-title":"Novel Solutions for Vaccines and Diagnostics to Combat Brucellosis","volume":"3","author":"Mandal","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1128\/JCM.03185-14","article-title":"Improved serodiagnosis of bovine brucellosis by novel synthetic oligosaccharide antigens representing the capping M epitope elements of Brucella O-Polysaccharide","volume":"53","author":"McGiven","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","unstructured":"Alton, G.G., Jones, L.M., Pietz, D.E., World Health Organization, and Food and Agriculture Organization of the United Nations (1975). Laboratory Techniques in Brucellosis, World Health Organization. [2nd ed.]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/jcm.33.8.2166-2170.1995","article-title":"Comparative evaluation of microagglutination test and serum agglutination test as supplementary diagnostic methods for brucellosis","volume":"33","author":"Baum","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0165-2427(90)90041-P","article-title":"Classical and alternative pathway haemolytic activities of ovine complement: Variations with age and sex","volume":"24","author":"Oswald","year":"1990","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.vetmic.2004.05.004","article-title":"Immunogenicity of recombinant Omp31 from Brucella melitensis in rams and serum bactericidal activity against B. ovis","volume":"102","author":"Estein","year":"2004","journal-title":"Vet. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vetimm.2013.04.003","article-title":"Immune response and serum bactericidal activity against Brucella ovis elicited using a short immunization schedule with the polymeric antigen BLSOmp31 in rams","volume":"154","author":"Clausse","year":"2013","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fvets.2017.00234","article-title":"Perspectives and outcomes of the activity of a reference laboratory for brucellosis","volume":"4","author":"Banai","year":"2018","journal-title":"Front. Vet. Sci."},{"key":"ref_29","unstructured":"Corbel, M.M.J. (2006). Brucellosis in Humans and Animals, WHO. WHO\/CDS\/EPR\/2006.7."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, D., Grill\u00f3, M.J., De Miguel, M.J., Ali, T., Arce-Gorvel, V., Delrue, R.M., Conde-\u00c1lvarez, R., Mu\u00f1oz, P., L\u00f3pez-Go\u00f1i, I., and Iriarte, M. (2008). Brucellosis vaccines: Assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002760"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: Protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/iai.61.9.3678-3687.1993","article-title":"Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei bound to bacterial toxoids","volume":"61","author":"Taylor","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:34Z","timestamp":1760134894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020317"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020317","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}